Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Peuskens

Showing results (51-60 of 75) with videos related to

Pageof 8
Sort By:
Schizophrenia Research|February 17, 2006
Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medicationMarc A De Hert, Ruud van Winkel, Dominique Van Eyck, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|May 26, 2012
Treatment of depression in first episode of schizophrenia: results from EUFESTJanusz K Rybakowski, Kristof Vansteelandt, Tomasz Szafranski, et al.
Pharmacoeconomics|January 19, 2006
Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysisDiana De Graeve, Ann Smet, Angelika Mehnert, et al.
International Clinical Psychopharmacology|December 13, 2006
Pharmacological treatment of severe dyslipidaemia in patients with schizophreniaLinda Hanssens, Marc De Hert, Dita Kalnicka, et al.
The Journal of Clinical Psychiatry|December 30, 2006
Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorderMarc De Hert, Dita Kalnicka, Ruud van Winkel, et al.
International Clinical Psychopharmacology|June 5, 2010
MTHFR genotype and differential evolution of metabolic parameters after initiation of a second generation antipsychotic: an observational studyRuud van Winkel, Tim Moons, Odette Peerbooms, et al.
Schizophrenia Research|September 26, 2006
Body weight and self-esteem in patients with schizophrenia evaluated with B-WISEMarc De Hert, Bie Peuskens, Ruud van Winkel, et al.
Psychiatry Research|November 10, 2009
Defining "good" and "poor" outcomes in patients with schizophrenia or schizoaffective disorder: a multidimensional data-driven approachIlya A Lipkovich, Walter Deberdt, John G Csernansky, et al.
Brain and Cognition|September 12, 2006
Action monitoring and perfectionism in anorexia nervosaGuido L M Pieters, Ellen R A de Bruijn, Yvonne Maas, et al.
The Journal of Clinical Psychiatry|August 7, 2008
Psychiatric diagnosis as an independent risk factor for metabolic disturbances: results from a comprehensive, naturalistic screening programRuud van Winkel, Jim van Os, Ivan Celic, et al.
Pageof 8

Showing results (51-60 of 75) with videos related to

Sort By:
Pageof 8
Schizophrenia Research|February 17, 2006
Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medicationMarc A De Hert, Ruud van Winkel, Dominique Van Eyck, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|May 26, 2012
Treatment of depression in first episode of schizophrenia: results from EUFESTJanusz K Rybakowski, Kristof Vansteelandt, Tomasz Szafranski, et al.
Pharmacoeconomics|January 19, 2006
Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysisDiana De Graeve, Ann Smet, Angelika Mehnert, et al.
International Clinical Psychopharmacology|December 13, 2006
Pharmacological treatment of severe dyslipidaemia in patients with schizophreniaLinda Hanssens, Marc De Hert, Dita Kalnicka, et al.
The Journal of Clinical Psychiatry|December 30, 2006
Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorderMarc De Hert, Dita Kalnicka, Ruud van Winkel, et al.
International Clinical Psychopharmacology|June 5, 2010
MTHFR genotype and differential evolution of metabolic parameters after initiation of a second generation antipsychotic: an observational studyRuud van Winkel, Tim Moons, Odette Peerbooms, et al.
Schizophrenia Research|September 26, 2006
Body weight and self-esteem in patients with schizophrenia evaluated with B-WISEMarc De Hert, Bie Peuskens, Ruud van Winkel, et al.
Psychiatry Research|November 10, 2009
Defining "good" and "poor" outcomes in patients with schizophrenia or schizoaffective disorder: a multidimensional data-driven approachIlya A Lipkovich, Walter Deberdt, John G Csernansky, et al.
Brain and Cognition|September 12, 2006
Action monitoring and perfectionism in anorexia nervosaGuido L M Pieters, Ellen R A de Bruijn, Yvonne Maas, et al.
The Journal of Clinical Psychiatry|August 7, 2008
Psychiatric diagnosis as an independent risk factor for metabolic disturbances: results from a comprehensive, naturalistic screening programRuud van Winkel, Jim van Os, Ivan Celic, et al.
Pageof 8